表紙:ファーマコビジランスの世界市場:産業動向、シェア、規模、成長、機会、および予測(2022年~2027年)
市場調査レポート
商品コード
1092014

ファーマコビジランスの世界市場:産業動向、シェア、規模、成長、機会、および予測(2022年~2027年)

Pharmacovigilance Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 149 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
ファーマコビジランスの世界市場:産業動向、シェア、規模、成長、機会、および予測(2022年~2027年)
出版日: 2022年06月13日
発行: IMARC Services Private Limited
ページ情報: 英文 149 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のファーマコビジランスの市場規模は、2021年は67億米ドルで、2022年から2027年の間に10.5%のCAGRを示し、2027年には118億米ドルに達すると予測されています。同市場の成長を後押しする主な要因には、生活習慣病の増加に伴う薬剤消費量の増加、薬物有害反応(ADR)の発生件数の増加、大手製薬会社による取り組みなどが挙げられます。

当レポートでは、世界のファーマコビジランス市場を調査しており、市場の概要、市場分析、サービスプロバイダー・製品ライフサイクル・タイプ・プロセスフロー・治療領域・エンドユーザー・地域別の分析、および競合情勢など、包括的な情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のファーマコビジランス市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場内訳:サービスプロバイダー別

  • 社内
  • 外部委託

第7章 市場内訳:製品ライフサイクル別

  • 前臨床
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第8章 市場内訳:タイプ別

  • 自発報告
  • 強化されたADR報告
  • ターゲットを絞った自発報告
  • コホートイベントモニタリング
  • EHRマイニング

第9章 市場内訳:プロセスフロー別

  • ケースデータ管理
    • 主な種類
  • シグナル検出
    • 主な種類
  • リスク管理システム
    • 主な種類

第10章 市場内訳:治療領域別

  • 腫瘍学
  • 神経学
  • 心臓病学
  • 呼吸器系
  • その他

第11章 市場内訳:エンドユーザー別

  • 製薬会社
  • バイオテクノロジー企業
  • 医療機器メーカー
  • その他

第12章 市場内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東とアフリカ
    • 国別の市場内訳

第13章 SWOT分析

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

第16章 価格分析

第17章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Accenture plc
    • ArisGlobal LLC
    • BioClinica Inc.(Cinven Partners LLP)
    • Capgemini
    • Cognizant
    • International Business Machines Corporation
    • ICON plc.
    • IQVIA Inc.
    • ITClinical
    • Parexel International Corporation
    • Wipro Limited
図表

List of Figures

  • Figure 1: Global: Pharmacovigilance Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Pharmacovigilance Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Pharmacovigilance Market: Breakup by Service Provider (in %), 2021
  • Figure 5: Global: Pharmacovigilance Market: Breakup by Product Life Cycle (in %), 2021
  • Figure 6: Global: Pharmacovigilance Market: Breakup by Type (in %), 2021
  • Figure 7: Global: Pharmacovigilance Market: Breakup by Process Flow (in %), 2021
  • Figure 8: Global: Pharmacovigilance Market: Breakup by Therapeutic Area (in %), 2021
  • Figure 9: Global: Pharmacovigilance Market: Breakup by End Use (in %), 2021
  • Figure 10: Global: Pharmacovigilance Market: Breakup by Region (in %), 2021
  • Figure 11: Global: Pharmacovigilance (In-house) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Pharmacovigilance (In-house) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Pharmacovigilance (Contract Outsourcing) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Pharmacovigilance (Contract Outsourcing) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Pharmacovigilance (Pre-clinical) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Pharmacovigilance (Pre-clinical) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Pharmacovigilance (Phase I) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Pharmacovigilance (Phase I) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Pharmacovigilance (Phase II) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Pharmacovigilance (Phase II) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Pharmacovigilance (Phase III) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Pharmacovigilance (Phase III) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Pharmacovigilance (Phase IV) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Pharmacovigilance (Phase IV) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Pharmacovigilance (Spontaneous Reporting) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Pharmacovigilance (Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Pharmacovigilance (Intensified ADR Reporting) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Pharmacovigilance (Intensified ADR Reporting) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Pharmacovigilance (Cohort Event Monitoring) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Pharmacovigilance (Cohort Event Monitoring) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Pharmacovigilance (EHR Mining) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Pharmacovigilance (EHR Mining) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Pharmacovigilance (Case Data Management) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Pharmacovigilance (Case Data Management) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Pharmacovigilance (Signal Detection) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Pharmacovigilance (Signal Detection) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: Global: Pharmacovigilance (Risk Management System) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: Global: Pharmacovigilance (Risk Management System) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: Global: Pharmacovigilance (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: Global: Pharmacovigilance (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Global: Pharmacovigilance (Neurology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Global: Pharmacovigilance (Neurology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: Global: Pharmacovigilance (Cardiology) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Global: Pharmacovigilance (Cardiology) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: Global: Pharmacovigilance (Respiratory Systems) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: Global: Pharmacovigilance (Respiratory Systems) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: Global: Pharmacovigilance (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: Global: Pharmacovigilance (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Global: Pharmacovigilance (Pharmaceuticals Companies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Global: Pharmacovigilance (Pharmaceuticals Companies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: Global: Pharmacovigilance (Biotechnology Companies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: Global: Pharmacovigilance (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: Global: Pharmacovigilance (Medical Device Companies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: Global: Pharmacovigilance (Medical Device Companies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: Global: Pharmacovigilance (Other End Uses) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: Global: Pharmacovigilance (Other End Uses) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: North America: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: North America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: United States: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: United States: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Canada: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Canada: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: Asia-Pacific: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: Asia-Pacific: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: China: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: China: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Japan: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Japan: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: India: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: India: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: South Korea: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: South Korea: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Australia: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Australia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Indonesia: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Indonesia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Europe: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Europe: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Germany: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Germany: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: France: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: France: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 87: United Kingdom: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 88: United Kingdom: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 89: Italy: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 90: Italy: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 91: Spain: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 92: Spain: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 93: Russia: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 94: Russia: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 95: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 96: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 97: Latin America: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 98: Latin America: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 99: Brazil: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 100: Brazil: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 101: Mexico: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 102: Mexico: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 103: Others: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 104: Others: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 105: Middle East and Africa: Pharmacovigilance Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 106: Middle East and Africa: Pharmacovigilance Market: Breakup by Country (in %), 2021
  • Figure 107: Middle East and Africa: Pharmacovigilance Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 108: Global: Pharmacovigilance Industry: SWOT Analysis
  • Figure 109: Global: Pharmacovigilance Industry: Value Chain Analysis
  • Figure 110: Global: Pharmacovigilance Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Pharmacovigilance Market Forecast: Breakup by Service Provider (in Million US$), 2022-2027
  • Table 3: Global: Pharmacovigilance Market Forecast: Breakup by Product Life Cycle (in Million US$), 2022-2027
  • Table 4: Global: Pharmacovigilance Market Forecast: Breakup by Type (in Million US$), 2022-2027
  • Table 5: Global: Pharmacovigilance Market Forecast: Breakup by Process Flow (in Million US$), 2022-2027
  • Table 6: Global: Pharmacovigilance Market Forecast: Breakup by Therapeutic Area (in Million US$), 2022-2027
  • Table 7: Global: Pharmacovigilance Market Forecast: Breakup by End Use (in Million US$), 2022-2027
  • Table 8: Global: Pharmacovigilance Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 9: Global: Pharmacovigilance Market: Competitive Structure
  • Table 10: Global: Pharmacovigilance Market: Key Players
目次
Product Code: SR0622A140_Report

The global pharmacovigilance market reached a value of US$ 6.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2027, exhibiting a CAGR of 10.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Pharmacovigilance (PV) is the pharmacological science concerning the detection, assessment, understanding and prevention of unfavorable effects with pharmaceutical products. It plays a pivotal role in identifying previously unknown adverse effects, recognizing changes in the frequency or severity, and assessing the risks and benefits of drugs to determine required actions. It also ensures the accuracy of communicated information to healthcare professionals and patients. At present, PV is widely used to understand the effects of drugs on individuals worldwide.

The increasing prevalence of lifestyle diseases, such as hypertension, diabetes, and cardiac disorders, has resulted in the rising consumption of drugs worldwide. This, in confluence with the growing incidences of adverse drug reactions (ADRs), represents one of the key factors driving the global pharmacovigilance market. Besides this, the key players are introducing advanced platforms to ensure automated ADR reporting, which is contributing to the market growth. They are also focusing on improving the manufacturing operations and streamlining research and development (R&D) on account of a competitive environment. Furthermore, leading pharmaceutical companies are undertaking numerous initiatives to conduct clinical trials and generate awareness about the proper utilization of medicines. This, in turn, is facilitating the growth of the pharmacovigilance market. Additionally, the coronavirus disease (COVID-19) outbreak has resulted in the urgent need for a vaccine, which has created numerous opportunities for the market players. Apart from this, pharmaceutical manufacturers are shifting towards outsourcing pharmacovigilance operations to third parties on account of the associated benefits, such as increasing internal resource flexibility and better outcomes over shorter periods.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacovigilance market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on service provider, product life cycle, type, process flow, therapeutic area and end use.

Breakup by Service Provider:

  • In-house
  • Contract Outsourcing

Breakup by Product Life Cycle:

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Type:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Breakup by Process Flow:

  • Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing and Reporting
  • Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review and Reporting
  • Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Breakup by Therapeutic Area:

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

Breakup by End Use:

  • Pharmaceuticals Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture plc, ArisGlobal LLC, BioClinica Inc. (Cinven Partners LLP), Capgemini, Cognizant, International Business Machines Corporation, ICON plc., IQVIA Inc., ITClinical, Parexel International Corporation and Wipro Limited.

Key Questions Answered in This Report:

  • How has the global pharmacovigilance market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmacovigilance market?
  • What are the key regional markets?
  • What is the breakup of the market based on the service provider?
  • What is the breakup of the market based on the product life cycle?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the process flow?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pharmacovigilance market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Contract Outsourcing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Phase I
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Phase II
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Phase III
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Phase IV
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 EHR Mining
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Market Trends
    • 9.1.2 Major Types
      • 9.1.2.1 Case Logging
      • 9.1.2.2 Case Data Analysis
      • 9.1.2.3 Medical Reviewing and Reporting
    • 9.1.3 Market Forecast
  • 9.2 Signal Detection
    • 9.2.1 Market Trends
    • 9.2.2 Major Types
      • 9.2.2.1 Adverse Event Logging
      • 9.2.2.2 Adverse Event Analysis
      • 9.2.2.3 Adverse Event Review and Reporting
    • 9.2.3 Market Forecast
  • 9.3 Risk Management System
    • 9.3.1 Market Trends
    • 9.3.2 Major Types
      • 9.3.2.1 Risk Evaluation System
      • 9.3.2.2 Risk Mitigation System
    • 9.3.3 Market Forecast

10 Market Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurology
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Cardiology
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Respiratory Systems
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Biotechnology Companies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Medical Device Companies
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Accenture plc
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 ArisGlobal LLC
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
    • 17.3.3 BioClinica Inc. (Cinven Partners LLP)
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 SWOT Analysis
    • 17.3.4 Capgemini
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
    • 17.3.5 Cognizant
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 International Business Machines Corporation
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
      • 17.3.6.4 SWOT Analysis
    • 17.3.7 ICON plc.
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 IQVIA Inc.
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 ITClinical
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
    • 17.3.10 Parexel International Corporation
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 SWOT Analysis
    • 17.3.11 Wipro Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis